drugset
Drugs / N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid
last change Dec 2025 re-read 3 minutes ago

N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid

also known as XC9
Developed for
influenza
Investigated by
Valenta Pharm JSC

Trials 3

today NCT07420985 · Ph 2 NCT07645534 · Ph 1 NCT06859333 · Ph 1
2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT07645534 Jul 2025 → Dec 2027 expected influenza Valenta Pharm JSC Recruiting No outcome recorded
Phase 1 NCT06859333 Jan → Dec 2025 overdue influenza Valenta Pharm JSC Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT07420985 Oct 2025 → Dec 2027 expected influenza Valenta Pharm JSC Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid “imidazolylethanamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid (XC9)” NCT07645534 ↗
2

“Imidazolyl ethanamide pentandioic acid + N,N'-bis-[2-(1,3-Diazocyclopenta2,4-dien-4-yl)ethyl] diamide of malonic acid” NCT07420985 ↗

NCT06859333 ↗
Known as XC9 “imidazolylethanamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid (XC9)” NCT07645534 ↗
Route Oral “Multiple Oral Administration” NCT06859333 ↗